Giuseppe Nardo

Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study

Introduction: First-line treatment options for EGFR-mutated NSCLC have expanded beyond osimertinib monotherapy following the FLAURA2 and MARIPOSA trials, which demonstrated improved long-term outcomes with combination strategies, albeit with increased toxicities. Given that rando...

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

Abstract Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I 3 LUNG ( NCT05537922 ) is currently the...